ASTRO 2021: Conventional vs Hypofractionated Radiation for High Risk Prostate Cancer Patients (CHIRP): 24 months Patient Reported Quality of Life Outcomes of the Randomized Phase II CHIRP Trial

(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting included a presentation by Dr. Fan Yang providing 24-month patient-reported quality of life outcomes from the randomized phase II trial of conventional versus hypofractionated radiation for high risk prostate cancer patients (CHIRP).